

Physician risk perceptions and surveillance practices for long-term effects in pediatric CML

Pediatric Hematology and Oncology

39, 453-467

DOI: [10.1080/08880018.2021.2017085](https://doi.org/10.1080/08880018.2021.2017085)

Citation Report

#	ARTICLE	IF	CITATIONS
1	Distribution and frequency of tyrosine kinase inhibitor-associated long-term complications in children with chronic myeloid leukemia. <i>Pediatric Blood and Cancer</i> , 2022, 69, e29786.	0.8	2
2	When should a Reduced intensity Conditioning (RIC) Hematopoietic Stem Cell Transplant (HSCT) be Considered in Pediatric CML-CP1?. <i>Transplantation and Cellular Therapy</i> , 2022, 28, 347-348.	0.6	0